Company Overview
| Stock Name | Henlius |
|---|---|
| Stock Code | 02696 |
| Company Full Name | To be extracted |
| Industry | 醫療保健 |
| Principal Activities | 公司主要於中國從事生物制藥業務，專注開發用於治療腫瘤及自身免疫疾病的生物類似藥及新藥。 |
| Listing Date | 2019-09-25 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市徐匯區虹梅路1801號凱科國際大廈A座9樓 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.henlius.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 49.60 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 34.2% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 320,892,160 |
Stock Connect Inclusion
| HK Market Cap | --- |
|---|
| 26Q2 Regular Review | |
| Inclusion Pathway | None |
|---|---|
| Est. Threshold | --- |
| Analysis Result | 无法确定入通路径 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 49.45 |
|---|---|
| First Day Open | HK$ 47.45 |
| First Day Change | -0.30% |
| First Day Volume | 6118470.0 |
| First Day Turnover | 295655000.0 |
Use of Proceeds
| Use of Proceeds | 1、約1,238.5百萬港元（或所得款項凈額的40.0%）將用于撥付持續進行的核心產品的臨床試驗、監管備案及注冊； 2、約464.5百萬港元（或所得款項凈額的15.0%）將用于撥付持續進行的其他候選生物類似藥（包括HLX12、HLX11及HLX14）的臨床試驗、監管備案及注冊； 3、約1,083.7百萬港元（或所得款項凈額的35.0%）將用于撥付持續進行的生物創新藥的臨床試驗、監管備案及注冊以及開發免疫腫瘤聯合療法； 4、約309.6百萬港元（或所得款項凈額的10.0%）將分配至營運資金及一般企業用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (5)
Overall Coordinators (7)
China International Capital Corporation Hong Kong Securities Limited CE AEN894
Merrill Lynch (Asia Pacific) Limited CE AAC198
BOCI ASIA LIMITED CE AET863
UBS Securities Hong Kong Limited CE BIN466
CMB International Capital Limited CE AVM940
Fosun International Securities Limited CE AAF432
Citigroup Global Markets Asia Limited CE AAA137
Joint Bookrunners (15)
China International Capital Corporation Hong Kong Securities Limited CE AEN894
Merrill Lynch (Asia Pacific) Limited CE AAC198
BOCI ASIA LIMITED CE AET863
UBS Securities Hong Kong Limited CE BIN466
CMB International Capital Limited CE AVM940
Fosun International Securities Limited CE AAF432
Citigroup Global Markets Asia Limited CE AAA137
HAITONG INTERNATIONAL SECURITIES COMPANY LIMITED CE AAF806
oOo Securities (HK) Group Limited CE AJH488
BNP PARIBAS SECURITIES (ASIA) LIMITED CE AAF669
ICBC INTERNATIONAL CAPITAL LIMITED CE AQW615
ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855
ABCI CAPITAL LIMITED CE AWL249
CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536
SBI China Capital Financial Services Limited CE ABD523
Joint Lead Managers (15)
China International Capital Corporation Hong Kong Securities Limited CE AEN894
Merrill Lynch (Asia Pacific) Limited CE AAC198
BOCI ASIA LIMITED CE AET863
UBS Securities Hong Kong Limited CE BIN466
CMB International Capital Limited CE AVM940
Fosun International Securities Limited CE AAF432
Citigroup Global Markets Asia Limited CE AAA137
HAITONG INTERNATIONAL SECURITIES COMPANY LIMITED CE AAF806
oOo Securities (HK) Group Limited CE AJH488
BNP PARIBAS SECURITIES (ASIA) LIMITED CE AAF669
ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299
ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855
ABCI Securities Company Limited CE ACX411
CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536
SBI China Capital Financial Services Limited CE ABD523
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Al-Rayyan Holding LLC | 704,999,520 HKD | — | 21.97% | — | 6 months | 2020-03-25 |
| 2 | AVICT Global Holdings Limited | 235,208,160 HKD | — | 7.33% | — | 6 months | 2020-03-25 |
| 3 | Henlius Biopharmaceuticals Inc. | 78,402,720 HKD | — | 2.44% | — | 6 months | 2020-03-25 |
| 4 | 浙江舒泰神投资有限公司 | 78,402,720 HKD | — | 2.44% | — | 6 months | 2020-03-25 |
Directors & Management
| Chairman | 張文杰 |
|---|---|
| Company Secretary | 王燕,陳秀玲 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 上海復星醫藥(集團)股份有限公司(59.63%);Liu Shi Kau Scott及關連人士(8.49%);Qatar Investment Authority(2.09%) |
|---|
